Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04736706 · ClinicalTrials.gov registry record · Phase 3

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

A Phase 3 study of Carcinoma, Renal Cell, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 3
Development phase
1,653
Enrollment target
20
Study locations

NCT04736706 is a Phase 3 study of Carcinoma, Renal Cell that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 1,653 participants, above the 235-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (603% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04736706, a Phase 3 study of Carcinoma, Renal Cell, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,653 participants
Enrollment target
20
Study locations

Study Summary

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

Conditions Studied

Carcinoma, Renal Cell

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Belzutifan
  • DRUG Lenvatinib
  • BIOLOGICAL Pembrolizumab/Quavonlimab

Study Locations (20)

California

  • UC San Diego ( Site 0050) - La Jolla
  • Cedars Sinai Medical Center ( Site 0027) - Los Angeles
  • University of California Irvine ( Site 0029) - Orange
  • UCLA Hematology Oncology Santa Monica ( Site 0048) - Santa Monica

Massachusetts

  • Massachusetts General Hospital ( Site 0094) - Boston
  • Beth Israel Deaconess Medical Center ( Site 0089) - Boston
  • Dana Farber Cancer Institute ( Site 0093) - Boston
  • Lahey Hospital & Medical Center ( Site 0090) - Burlington

Georgia

  • University Cancer & Blood Center, LLC ( Site 0057) - Athens
  • Emory University Winship Cancer Institute ( Site 0012) - Atlanta

Michigan

  • Henry Ford Hospital ( Site 0038) - Detroit
  • Cancer & Hematology Centers of Western Michigan ( Site 0018) - Grand Rapids

Alabama

  • The University of Alabama at Birmingham ( Site 0010) - Birmingham

Connecticut

  • Hartford Hospital ( Site 0024) - Hartford

Florida

  • Advent Health Hematology & Oncology ( Site 0003) - Orlando

Illinois

  • Rush University Medical Center ( Site 0040) - Chicago

Trial Details

FieldValue
Enrollment Target 1,653 participants
Start Date 2021-04-14
Est. Completion 2026-10-29
Phase Phase 3

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04736706

The ClinicalTrials.gov registry entry for NCT04736706 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,653 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 235-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (603% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT04736706 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Massachusetts, Georgia.

Frequently Asked Questions

What is clinical trial NCT04736706 about?

NCT04736706 is a clinical study titled "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)". The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary...

What is the current status of trial NCT04736706?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,653 participants. The study started on 2021-04-14. Estimated completion is 2026-10-29.

What conditions does trial NCT04736706 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell.

What interventions are being tested in trial NCT04736706?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Belzutifan (DRUG), Lenvatinib (DRUG), Pembrolizumab/Quavonlimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04736706?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04736706 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Renal Cell

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.